Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportPoster Presentations - Physicians/Scientists/Pharmacists

Complete metabolic tumor response, assessed by 18FDG-PET, after induction chemotherapy in patients (pts) with locally advanced non small cell lung carcinoma (NSCLC) predicts longer time to progression (TTP) and survival (S)

Hendrik Everaert, Denis Schallier, Bart Neyns, Nick Baelde, Marc Meysman, Jacques De Greve, Johan de Mey, Christian Vanhove and Axel Bossuyt
Journal of Nuclear Medicine May 2006, 47 (suppl 1) 472P;
Hendrik Everaert
1Nuclear Medicine, AZ VUB, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Denis Schallier
2Oncology, AZ VUB, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bart Neyns
2Oncology, AZ VUB, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nick Baelde
3Radiology, AZ VUB, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Meysman
4Pneumology, AZ VUB, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacques De Greve
2Oncology, AZ VUB, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johan de Mey
3Radiology, AZ VUB, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Vanhove
1Nuclear Medicine, AZ VUB, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Axel Bossuyt
1Nuclear Medicine, AZ VUB, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1747

Objectives: Serial imaging yields predictive information early in the onset of chemotherapy in a number of cancers. We have evaluated the early effects of induction chemotherapy in locally advanced NSCLC by multi-slice CT and 18FDG-PET.

Methods: Twenty-one pts (median age 70, 14 m / 7 f) with newly diagnosed stage III NSCLC underwent contrast enhanced multi-slice CT and 18FDG-PET with attenuation correction, at baseline and after 3 cycles of induction chemotherapy (paclitaxel, carboplatin and gemcitabine = PCG). For CT, pts were scanned on a Siemens Sensation16 scanner, responses in tumour dimensions were classified according the Response Evaluation Criteria in Solid Tumors (J Natl Cancer Inst 2000;92:205-16) as progressive disease (PD), stable disease (SD), partial response (PR) or complete remission (CR). PET images were acquired in 3D on a Siemens Accel camera starting 60 min. after administration of 307-606 MBq 18FDG. The maximal standerdized uptake value (SUVmax) within the tumour was measured. PET responses were classified either as complete (resolution of enhanced uptake within the tumour) or non-complete. For each subgroup of pts, classified according CT and PET responses, TTP and S were calculated and the data were analysed statistically according to Kaplan-Meier and log rang test. Median follow-up interval was 19 months with 11 deaths.

Results: At baseline all NSCLC showed intense 18FDG uptake: SUVmax 10.9 ± 5.1 on average. A complete metabolic response was measured in 6 pts, in the remaining 15 pts residual 18FDG accumulation within the tumour was observed after 3 cycles of PCG. According to CT there were 9 pts with SD and 12 pts with PR. None of the pts was classified as PD or CR. Table 1 summarizes for the different CT and PET response categories TTP and S (in days).

Conclusions: In pts with locally advanced NSCLC treated with PCG, assessment of response to treatment using 18FDG-PET appears to be a more sensitive tool compared to MSCT. Complete metabolic response on 18FDG-PET is associated with a significantly longer TTP and S as compared to non-complete responders.


Embedded Image

  • Society of Nuclear Medicine, Inc.
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 47, Issue suppl 1
May 1, 2006
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Complete metabolic tumor response, assessed by 18FDG-PET, after induction chemotherapy in patients (pts) with locally advanced non small cell lung carcinoma (NSCLC) predicts longer time to progression (TTP) and survival (S)
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Complete metabolic tumor response, assessed by 18FDG-PET, after induction chemotherapy in patients (pts) with locally advanced non small cell lung carcinoma (NSCLC) predicts longer time to progression (TTP) and survival (S)
Hendrik Everaert, Denis Schallier, Bart Neyns, Nick Baelde, Marc Meysman, Jacques De Greve, Johan de Mey, Christian Vanhove, Axel Bossuyt
Journal of Nuclear Medicine May 2006, 47 (suppl 1) 472P;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Complete metabolic tumor response, assessed by 18FDG-PET, after induction chemotherapy in patients (pts) with locally advanced non small cell lung carcinoma (NSCLC) predicts longer time to progression (TTP) and survival (S)
Hendrik Everaert, Denis Schallier, Bart Neyns, Nick Baelde, Marc Meysman, Jacques De Greve, Johan de Mey, Christian Vanhove, Axel Bossuyt
Journal of Nuclear Medicine May 2006, 47 (suppl 1) 472P;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Poster Presentations - Physicians/Scientists/Pharmacists

  • Selective internal radiotherapy (SIRT) of liver metastases and hepatocellular carcinoma: Is the posttherapeutic distribution of SIR Spheres® related to the pretherapeutic deposition of MAA in FDG positive lesions?
  • Mononuclear Tc-99m-chelate-conjugated oligo-aspartic acid as a new bone imaging agent
  • Tritium labeled choline and fluoroethylcholine – In vitro evaluation for visualization of prostate cancer with PET
Show more Poster Presentations - Physicians/Scientists/Pharmacists

Oncology Track

  • Iodine-131 mIBG infusion: An analysis of waste activity
  • Early prediction of response to chemotherapy using FDG PET/CT in advanced/metastatic non-small cell lung cancer
  • Clinical study using L-3-[18F] fluoro-α-methyltyrosine (FAMT) and 18F-FDG PET for maxillofacial tumor: Comparative immunohistopathological analysis with cellular proliferation (Ki-67) and amino-acid transporter expression (LAT-1)
Show more Oncology Track

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire